Transmission of vaccinia virus and rationale for measures for prevention

被引:18
作者
Lane, JM
Fulginiti, VA
机构
[1] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA
[2] Emory Sch Med, Dept Family & Prevent Med, Atlanta, GA USA
[3] Univ Colorado, Dept Pediat, Denver, CO 80202 USA
关键词
D O I
10.1086/377236
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Currently, health care workers (HCWs) in the United States are being vaccinated against smallpox, and there is a possibility that this will be expanded to a more widespread vaccination program. Inadvertent transmission of vaccinia virus to patients with illnesses that are contraindications to vaccination is theoretically possible. Vaccinia virus is shed from the vaccination lesion of healthy primary vaccinees from approximately the third day to the end of the third week after vaccination; transmission of vaccinia virus is rare but does occur. Prudent management of the vaccination site by HCWs should virtually eliminate transmission. We recommend that vaccinated HCWs cover the site with loose gauze dressings and, when caring for patients with immunosuppression or extensive disruptive skin disorders, cover the dressings with semipermeable membranes. The evidence for respiratory spread of vaccinia virus is not compelling, and therefore droplet or airborne infection precautions should not be necessary, even for vaccinated HCWs who are caring for patients who experienced serious adverse events after smallpox vaccination in the past.
引用
收藏
页码:281 / 284
页数:4
相关论文
共 18 条
[1]  
[Anonymous], NY TIMES 1115
[2]   ANTIBODY RESPONSE TO CUTANEOUS INOCULATION WITH VACCINIA VIRUS - VIREMIA + VIRURIA IN VACCINATED CHILDREN [J].
BLATTNER, RJ ;
HEYS, FM ;
AKSU, I ;
NORMAN, JO .
JOURNAL OF PEDIATRICS, 1964, 64 (06) :839-+
[3]  
Kohn William G, 2003, MMWR Recomm Rep, V52, P1
[4]   SAFETY OF AND IMMUNOLOGICAL RESPONSE TO A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING HIV ENVELOPE GLYCOPROTEIN [J].
COONEY, EL ;
COLLIER, AC ;
GREENBERG, PD ;
COOMBS, RW ;
ZARLING, J ;
ARDITTI, DE ;
HOFFMAN, MC ;
HU, SL ;
COREY, L .
LANCET, 1991, 337 (8741) :567-572
[5]  
Fenner F, 1988, SMALLPOX ITS ERADICA, P122
[6]  
FENNER F, 1988, SMALLPOX ITS ERADICA, P540
[7]   ROLE OF ANTIBODY, DELAYED HYPERSENSITIVITY, AND INTERFERON PRODUCTION IN RECOVERY OF GUINEA PIGS FROM PRIMARY INFECTION WITH VACCINIA VIRUS [J].
FRIEDMAN, RM ;
BARON, S ;
STEINMULLER, RI ;
BUCKLER, CE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1962, 116 (03) :347-&
[8]  
Fulginiti VA, 1968, BIRTH DEFECTS OAS, V4, P129
[9]   VACCINATION OF VACCINIA-NAIVE ADULTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP160 RECOMBINANT VACCINIA VIRUS IN A BLINDED, CONTROLLED, RANDOMIZED CLINICAL-TRIAL [J].
GRAHAM, BS ;
BELSHE, RB ;
CLEMENTS, ML ;
DOLIN, R ;
COREY, L ;
WRIGHT, PF ;
GORSE, GJ ;
MIDTHUN, K ;
KEEFER, MC ;
ROBERTS, NJ ;
SCHWARTZ, DH ;
AGOSTI, JM ;
FERNIE, BF ;
STABLEIN, DM ;
MONTEFIORI, DC ;
LAMBERT, JS ;
HU, SL ;
ESTERLITZ, JR ;
LAWRENCE, DN ;
KOFF, WC .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (02) :244-252
[10]  
GURVICH EB, 1974, J HYG EPID MICROB IM, V18, P69